Drug Trial Radar · NCT02914535
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,173
Actual
Start
Feb 23, 2017
Primary completion
Sep 8, 2026
Study completion Sep 8, 2026
Sponsor
- Lead sponsor
- Alfasigma S.p.A.Industry
- Sponsor type
- Industry
- Collaborators
- Gilead Sciences
- First posted
- Sep 26, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative colitis (UC).
Conditions
- Ulcerative Colitis
Interventions
FilgotinibDrug
Tablet(s) administered orally once daily
PlaceboDrug
Tablet(s) administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Safety Profile of Filgotinib Evaluated by Proportion of Participants Experiencing Adverse Events and Abnormal Clinical Laboratory TestsTime frame: Up to 336 weeks plus 30 days
Locations
323 sites in 39 countries. Site status is shown where the registry gives one.
Digestive Health Specialists Of The Southeast
Dothan, Alabama
Mayo Clinic Arizona
Scottsdale, Arizona
VA Long Beach Healthcare System
Long Beach, California
Cedars Sinai Medical Center
Los Angeles, California
South Denver Gastroenterology, PC
Lone Tree, Colorado
Connecticut GI PC-Research Division
Farmington, Connecticut
UF Clinical Research Center
Gainesville, Florida
Florida Research Institute
Lakewood Rch, Florida
University of Miami Crohn's and Colitis Center
Miami, Florida
Cordova Research Institute
Miami, Florida
Gastroenterology Group of Naples
Naples, Florida
Advanced Medical Research Center
Port Orange, Florida
Tampa General Hospital
Tampa, Florida
Florida Medical Clinic, P.A
Zephyrhills, Florida
Gastroenterology Associates Of Central Georgia, LLC
Macon, Georgia
Gastrointestinal Specialists of Georgia
Marietta, Georgia
Atlanta Gastroenterology Specialist, PC
Suwanee, Georgia
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Louisville, Clinical Trials Unit
Louisville, Kentucky
Delta Research Partners, LLC
Monroe, Louisiana
Louisiana Research Center, LLC
Shreveport, Louisiana
Investigative Clinical Research
Annapolis, Maryland
MGG Group Co., Inc., Chevy Chase Clinical Research
Chevy Chase, Maryland
Gastro Center of Maryland
Columbia, Maryland
Meritus Center for Clinical Research
Hagerstown, Maryland
Massachusetts General Hospital - Crohn's and Colitis Center
Boston, Massachusetts
Clinical Research Institute of Michigan, LLC
Chesterfield, Michigan
Center for Digestive Health Research
Troy, Michigan
Mayo Clinic
Rochester, Minnesota
Kansas City Research Institute
Kansas City, Missouri
Washington University School of Medicine
St Louis, Missouri
NY Scientific
Brooklyn, New York
NYU Langone Long Island Clinical Research Associates
Great Neck, New York
Carolina's GI Research LLC
Raleigh, North Carolina
Fargo Gastroenterology and Hepatology Clinic
Fargo, North Dakota
Consultants for Clinical Research
Cincinnati, Ohio
UC Health Physicians Clifton
Cincinnati, Ohio
Great Lakes Gastroenterology Research, LLC
Mentor, Ohio
Gastroenterology Associates of Orangeburg
Orangeburg, South Carolina
Rapid City Medical Center
Rapid City, South Dakota
Showing 40 of 323 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.